LEADER 05177nam 22006732 450 001 9910454531203321 005 20151005020624.0 010 $a0-511-69892-5 010 $a1-107-20085-7 010 $a1-282-30321-X 010 $a9786612303210 010 $a0-511-59597-2 010 $a0-511-59637-5 010 $a0-511-59347-3 010 $a0-511-59254-X 010 $a0-511-59677-4 010 $a0-511-59540-9 035 $a(CKB)1000000000784242 035 $a(EBL)452000 035 $a(OCoLC)609843039 035 $a(SSID)ssj0000233927 035 $a(PQKBManifestationID)11209627 035 $a(PQKBTitleCode)TC0000233927 035 $a(PQKBWorkID)10234880 035 $a(PQKB)11750493 035 $a(UkCbUP)CR9780511596773 035 $a(MiAaPQ)EBC452000 035 $a(MiAaPQ)EBC4949864 035 $a(Au-PeEL)EBL452000 035 $a(CaPaEBR)ebr10329781 035 $a(Au-PeEL)EBL4949864 035 $a(CaONFJC)MIL230321 035 $a(OCoLC)819628537 035 $a(EXLCZ)991000000000784242 100 $a20090716d2009|||| uy| 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aRecombinant antibodies for immunotherapy /$fedited by Melvyn Little$b[electronic resource] 210 1$aCambridge :$cCambridge University Press,$d2009. 215 $a1 online resource (xiv, 419 pages) $cdigital, PDF file(s) 300 $aTitle from publisher's bibliographic system (viewed on 05 Oct 2015). 311 $a0-521-88732-1 320 $aIncludes bibliographical references and index. 327 $aHumanization of recombinant antibodies / Jose? W. Saldanha -- Immunogenicity assessment of antibody therapeutics / Philippe Stas [and others] -- In vitro screening for antibody immunogenicity / Frank J. Carr and Matthew B. Baker -- Antibody libraries from nai?ve V gene sources / Gerald Beste and David Lowe -- Antibodies from IgM libraries / Stefan Knackmuss and Vera Molkenthin -- Generation and screening of synthetic human combinatorial antibody library HuCAL GOLD / Ingo M. Klagge -- Therapeutic antibodies from XenoMouse transgenic mice / Aya Jakobovits -- VelocImmune : immunoglobulin variable region humanized mice / Andrew Murphy -- Mechanisms of tumour cell killing by therapeutic antibodies / Ross Stewart and Carl Webster -- Optimization of Fc domains to enhance antibody therapeutics / Greg A. Lazar and Aaron K. Chamberlain -- Glycoengineered therapeutic antibodies / Peter Bru?nker, Peter Sondermann, and Pablo Uman?a -- Monoclonal antibodies for the delivery of cytotoxic drugs / David J. King. 327 $aImmunotherapy with radio-immune conjugates / Christina A. Kousparou and Agamemnon A. Epenetos -- Immunotherapeutic antibody fusion proteins / Nigel S. Courtenay-Luck and David Jones -- Alternative antibody formats / Fabrice Le Gall and Melvyn Little -- Single-domain antibodies / Serge Muyldermans, Gholamreza Hassanzadeh Ghassabeh, and Dirk Saerens -- Engineering of non-CDR loops in immunoglobulin domains / Florian Ru?ker and Gordana Wozniak-Knopp -- Alternative scaffolds : expanding the options of antibodies / Andreas Plu?ckthun -- Polymer fusions to increase antibody half-lives : PEGylation and other modifications / Sam P. Heywood and David P. Humphreys -- Extending antibody half-lives with albumin / Jan Terje Andersen and Inger Sandlie -- A stem cell-based platform for the discovery and development of antitumor therapeutic antibodies to novel targets / Jennie P. Mather [and others] -- Antibody directed enzyme prodrug therapy (ADEPT) / Helen L. Lowe [and others] -- Immune privilege and tolerance -- therapeutic antibody approaches / Daron Forman [and others] -- Antibody therapeutics : business achievements and business outlook / Christophe Bourrilly. 330 $aRecombinant Antibodies for Immunotherapy provides a comprehensive overview of the field of monoclonal antibodies (mAbs), a market that has grown tremendously in recent years. Twenty-five articles by experienced and innovative authors cover the isolation of specific human mAbs, humanization, immunogenicity, technologies for improving efficacy, 'arming' mAbs, novel alternative Ab constructs, increasing half-lives, alternative concepts employing non-immunoglobulin scaffolds, novel therapeutic approaches, a market analysis of therapeutic mAbs, and future developments in the field. The concepts and technologies are illustrated by examples of recombinant antibodies being used in the clinic or in development. This book will appeal to both newcomers and experienced scientists in the field, biology and biotechnology students, research and development departments in the pharmaceutical industry, medical researchers, clinicians, and biotechnology investors. 606 $aMonoclonal antibodies$xTherapeutic use 615 0$aMonoclonal antibodies$xTherapeutic use. 676 $a615/.37 702 $aLittle$b Melvyn$f1945- 801 0$bUkCbUP 801 1$bUkCbUP 906 $aBOOK 912 $a9910454531203321 996 $aRecombinant antibodies for immunotherapy$92489095 997 $aUNINA